Identification of domains conferring ligand binding specificity to the prostanoid receptor - Studies on chimeric prostacyclin/prostaglandin D receptors

被引:41
作者
Kobayashi, T [1 ]
Kiriyama, M [1 ]
Hirata, T [1 ]
Hirata, M [1 ]
Ushikubi, F [1 ]
Narumiya, S [1 ]
机构
[1] KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN
关键词
D O I
10.1074/jbc.272.24.15154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To identify domains conferring ligand binding specificity to prostanoid receptors, we constructed a series of chimeric receptors by successively replacing the regions from the carboxyl-terminal tail of mouse prostacyclin (prostaglandin I (PGI)) receptor (mIP) with the corresponding regions of the mouse PGD receptor (mDP), The mIP receptor expressed in COS 7 cells bound [H-3]iloprost, a PGI(2) analog and [H-3]PGE(1) with K-d values of 13 and 27 nM, respectively, This receptor did not bind [H-3]PGD(2), [H-3]PGE(2), and [H-3]PGF(2 alpha). The mDP receptor bound only [H-3]PGD(2) with a K-d value of 43 nM, The chimeric IPN-VII/DPC receptor with replacement of the carboxyl tail of the mIP receptor with that of the mDP receptor showed 12-16-fold higher affinities for [H-3]iloprost and [H-3]PGE(1) than the mIP receptor, The region extending from the sixth transmembrane domain to the carboxyl terminus of the mIP receptor was next replaced with the corresponding region of the mDP receptor, This chimeric IPN-V/DPVI-C receptor acquired the ability to bind [H-3]PGD(2) and [H-3]PGE(2) without decreasing the affinities of the mIP receptor to [H-3]iloprost and [H-3]PGE(1). These binding characteristics did not change when the fourth and fifth transmembrane domains of the mIP receptor were further replaced with She corresponding regions of the mDP receptor, However, when the first extracellular to second intracellular loop of the mIP receptor containing the third transmembrane domain was further replaced with those of the mDP receptor, the affinities for [H-3]PGE(1), [H-3]PGE(2), and [3H]iloprost were markedly decreased, whereas that far [H-3]PGD(2) was increased by about 2-fold, [H-3]PGF(2 alpha) showed no affinity for the mIP, mDP, and all the chimeric receptors. These results suggest that She sixth to seventh transmembrane domain of the mIP receptor confers the specificity of this receptor to bind selectively to PGE(1) and not to PGE(2) and that the third transmembrane domain of the mDP, receptor confers the selective binding of PGD(2) to this receptor.
引用
收藏
页码:15154 / 15160
页数:7
相关论文
共 38 条
[1]   MOLECULAR-CLONING AND CHARACTERIZATION OF THE HUMAN PROSTANOID DP RECEPTOR [J].
BOIE, Y ;
SAWYER, N ;
SLIPETZ, DM ;
METTERS, KM ;
ABRAMOVITZ, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (32) :18910-18916
[2]  
COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643
[3]   STRUCTURE-FUNCTION ANALYSIS OF THE BETA-ADRENERGIC-RECEPTOR [J].
DIXON, RAF ;
SIGAL, IS ;
STRADER, CD .
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1988, 53 :487-497
[4]   LIPOFECTION - A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE [J].
FELGNER, PL ;
GADEK, TR ;
HOLM, M ;
ROMAN, R ;
CHAN, HW ;
WENZ, M ;
NORTHROP, JP ;
RINGOLD, GM ;
DANIELSEN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7413-7417
[5]  
FONG TM, 1992, J BIOL CHEM, V267, P25668
[6]   STRUCTURAL BASIS OF BETA-ADRENERGIC-RECEPTOR SUBTYPE SPECIFICITY STUDIED WITH CHIMERIC BETA-1-ADRENERGIC BETA-2-ADRENERGIC RECEPTORS [J].
FRIELLE, T ;
DANIEL, KW ;
CARON, MG ;
LEFKOWITZ, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (24) :9494-9498
[7]  
FUNK CD, 1993, MOL PHARMACOL, V44, P934
[8]   DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST [J].
GETHER, U ;
JOHANSEN, TE ;
SNIDER, RM ;
LOWE, JA ;
NAKANISHI, S ;
SCHWARTZ, TW .
NATURE, 1993, 362 (6418) :345-348
[9]   2 NONPEPTIDE TACHYKININ ANTAGONISTS ACT THROUGH EPITOPES ON CORRESPONDING SEGMENTS OF THE NK1 AND NK2 RECEPTORS [J].
GETHER, U ;
YOKOTA, Y ;
EMONDSALT, X ;
BRELIERE, JC ;
LOWE, JA ;
SNIDER, RM ;
NAKANISHI, S ;
SCHWARTZ, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :6194-6198
[10]  
HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213